Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial

Blood blood.2025031313.

https://doi.org/10.1182/blood.2025031313

Published: 2025

Includes: Supplemental data

Journal Articles

Trials in progress: Design of a registrational Phase 2 trial (ALLOHA) using an external control arm for TSC-101 for prevention of relapse post allogeneic HCT in patients with ALL, AML, or MDS

Blood (2025) 146 (Supplement 1): 2400.

https://doi.org/10.1182/blood-2025-2400

Published: 2025

Journal Articles

Primary results from Equator, a Phase 3 double-blind, randomized placebo-controlled study evaluating itolizumab in combination with corticosteroids as initial treatment of acute graft-versus-host disease.

John Koreth, Maria Carmen Martinez Munoz, Jeremy Pantin, Shukaib Arslan, Jaime Sanz, Alison Loren, Benedetta Rambaldi, Elisa Sala, Avichai Shimoni, Tsila Zuckerman, Corey Cutler, Lisette Acevedo, Kham Phenis, Eugene Sun, Stephen Connelly, Joel Rothman

Blood (2025) 146 (Supplement 1): 274.

https://doi.org/10.1182/blood-2025-274

Published: 2025

Journal Articles

Orca-T improves chronic graph-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, Phase 3 trial

Blood (2025) 146 (Supplement 1): 2477.

https://doi.org/10.1182/blood-2025-2477

Published: 2025

Journal Articles

Observational comparison of orca-T to registry-based post-transplant cyclophosphamide patients using matched unrelated donors

Blood (2025) 146 (Supplement 1): 6029.

https://doi.org/10.1182/blood-2025-6029

Published: 2025

Journal Articles

High-dose cryopreserved bone marrow from deceased donors may reduce relapse in HLA-mismatched allogeneic transplantation: Day 180 post-transplant HOPE update

Sagar Munjal, Muneer Abidi, Jeremy Pantin, Preethi Prasad, Vicki Graves, Scott Goebel, Erik Woods

Blood (2025) 146 (Supplement 1): 5976.

https://doi.org/10.1182/blood-2025-5976

Published: 2025

Journal Articles

Healthcare Resource Utilization and Costs Associated with Managing CRS and ICANS in Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Receiving Obecabtagene autoleucel (obe-cel)

Bijal D Shah, Jeremy Pantin, Karamjeet S Sandhu, Elias Jabbour, Jae H. Park, Paul Shaughnessy, Mehrdad Abedi, Michael R Bishop, Daniel J. DeAngelo, Wolfram Brugger, Martin Brown, Dilip Patel, Claire Roddie, Aaron C. Logan

Blood (2024) 144 (Supplement 1): 4837.

https://doi.org/10.1182/blood-2024-205694

Published: 2024

Journal Articles

Comparison of 15- Vs. 30-Day Remote Patient Monitoring for Outpatient Chimeric Antigen Receptor T-Cell Therapy (CAR-T) across a Large Health System

Tonya Cox, Nicole Zahradka, Casey Martin, Betsy Blunk, Rocky L. Billups, Sarah Meissner, Hannah Sowell, Stephanie Larson, Meredith Perez, Aravind Ramakrishnan, Paul Shaughnessy, Ashleigh Smith, Michael T. Tees, Jeremy Pantin, Benjamin Zaniello, Navneet Majhail, Minoo Battiwalla

Blood (2024) 144 (Supplement 1): 2300.

https://doi.org/10.1182/blood-2024-211566

Published: 2024

Journal Articles

Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients

Blood (2024) 144 (Supplement 1): 694.

https://doi.org/10.1182/blood-2024-205917

Published: 2024

Journal Articles

Standardization of Outpatient Care after CAR-T Therapy across a Large Cell Therapy Network- through Technology and Decentralized Virtual Nurses: Preliminary Results

Blood (2023) 142 (Supplement 1): 254.

https://doi.org/10.1182/blood-2023-187253

Published: 2023

Journal Articles

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)

Minoo Battiwalla, MD, Carlos Bachier, MD, Vikas Bhushan, MD, Michael J. Eckrich, MD MPH, Alireza Eghtedar, MD, Haydar Frangoul, MD, Suman Kambhampati, MD, Shahbaz Malik, MD, Peter A. McSweeney, MD, Jeremy Pantin, MBBS, Aravind Ramakrishnan, MD, Hana Safah, MD, Paul J Shaughnessy, MD, Betsy Blunk, BSN, RN, BMTCN, Tonya Cox, BSN, RN, Rocky Billups, MS, Charles F. Lemaistre, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-139121

Published: 2020

Journal Articles

Indoximod Combined with Standard Induction Chemotherapy Is Well Tolerated and Induces a High Rate of Complete Remission with MRD-Negativity in Patients with Newly Diagnosed AML: Results from a Phase 1 Trial

Ashkan Emadi, MD PhD, Vu H. Duong, MD, Jeremy Pantin, MD, Mohammad Imran, MD, Rima Koka, MD PhD, Zeba Singh, MBBS, Edward A. Sausville, MD PhD, Jennie Y. Law, MD, Seung Tae Lee, MD PhD, Huidong Shi, PhD, Ravindra Kolhe, MD PhD, Maria R. Baer, MD, Michael R. Loken, PhD, Eugene P. Kennedy, MD, Charles Link, MD, David H. Munn, MD

Blood (2018) 132 (Supplement 1): 332.

https://doi.org/10.1182/blood-2018-99-117433

Published: 2018

Journal Articles

Intrabone Delivery of CD34+ Cells Using an Optimized Delivery System Does Not Enhance Engraftment in a Rhesus Macaque Model of Hematopoietic Stem Cell Transplantation

Blood (2018) 132 (Supplement 1): 5677.

https://doi.org/10.1182/blood-2018-99-114730

Published: 2018

Journal Articles

Molecular Characterization By Cancer Immune Profiling in Acute Promyelocytic Leukemia (APL) May Identify Patients at Risk of Early Death

Ravindra Kolhe, MD PhD, Chetan Pundkar, DVM, Ashis Mondal, PhD, Jeremy Pantin, MBBS, Vamsi Kota, MBBS, Amber Clemmons, Anand Jillella, MD

Blood (2017) 130 (Supplement 1): 4976.

https://doi.org/10.1182/blood.V130.Suppl_1.4976.4976

Published: 2017

Journal Articles

Intermediate-Dose Cyclophosphamide Versus Plerixafor and Granulocyte Colony Stimulating Factor (G-CSF) for Peripheral Blood Progenitor Cell (PBPC) Mobilization in Patients with Multiple Myeloma (MM) Treated with Novel Induction Chemotherapies – A Multicenter Analysis

Farrukh Awan, MD, MS, Samith Thomas Kochuparambil, Michael Craig, Aaron Cumpston, PharmD, Sonia Leadmon, BS, Kathy Watkins, David Deremer, Jeremy Pantin, MD, Vamsi Kota, MBBS, Anand P. Jillella, MD, Mehdi Hamadani, MD

Blood (2012) 120 (21): 4409.

https://doi.org/10.1182/blood.V120.21.4409.4409

Published: 2012

Journal Articles

Co-Infusion of Allogeneic Cord Blood with Haploidentical CD34+ Cells Improved Transplant Outcome for Patients with Severe Aplastic Anemia Undergoing Cord Blood Transplantation

Blood (2011) 118 (21): 654.

https://doi.org/10.1182/blood.V118.21.654.654

Published: 2011

Journal Articles

A Phase I Trial of Adoptively Transferred Ex-Vivo Expanded Autologous Natural Killer (NK) Cells Following Treatment with Bortezomib to Sensitize Tumors to NK Cell Cytotoxicity

Robert N Reger, Maria Berg, Andreas Lundqvist, PhD, Theresa Donohue, MHS, PA-C, Mattias Carlsten, MD Ph.D, Dawn M Betters, Ph.D, Lisa Cook, RN, BSN, Catalina Ramos, RN, BSN, Sophia Grasmeder, RN, BSN, OCN, Su Su, MD, PhD, David Stroncek, MD, Jeremy Pantin, MD, Keyvan Keyvanfar, BS, Cristian A. Carvallo, MD, Hahn Khuu, MD, Richard Childs, MD

Blood (2011) 118 (21): 1001.

https://doi.org/10.1182/blood.V118.21.1001.1001

Published: 2011

Journal Articles

Adoptive Transfer of Escalating Doses of Ex Vivo Expanded Autologous Natural Killer (NK) Cells In Patients with Advanced Malignancies Following Bortezomib Treatment to Sensitize to NK-TRAIL Cytotoxicity

Aleah Smith, Hahn Khuu, MD, Dawn M Betters, RN, Lisa Cook, RN, BSN, Catalina Ramos, RN, BSN, Sophia Grasmeder, RN, BSN, OCN, Maria Berg, Rebecca Lopez, PhD, Su Su, MD, PhD, Vicki Fellowes, MT, David Stroncek, MD, Jeremy Pantin, MD, Sumi Vasu, MD, Theresa Donohue, MHS, PA-C, Keyvan Keyvanfar, BS, Richard Childs, MD

Blood (2010) 116 (21): 4296.

https://doi.org/10.1182/blood.V116.21.4296.4296

Published: 2010

Journal Articles

Long-Term Follow-up of Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Severe Paroxysmal Nocturnal Hemoglobinuria

Jeremy Pantin, MD, Xin Tian, Nancy Geller, PhD, Catalina Ramos, CRN, Lisa Cook, CRN, Sophia Grasmeder, CRN, Philip Scheinberg, MD, Neal S. Young, MD, Sumithira Vasu, MD, Theresa Donohue, MHS, PA-C, Richard Childs, MD

Blood (2010) 116 (21): 3505.

https://doi.org/10.1182/blood.V116.21.3505.3505

Published: 2010

Journal Articles

Absence of Graft Failure and Excellent Long Term Survival Following Fludarabine-Based Reduced Intensity Hematopoietic Stem Cell Transplantation In Heavily Transfused Patients with ATG-Refractory Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes

Jeremy Pantin, MD, Xin Tian, Ph.D., Nancy Geller, Ph.D., Catalina Ramos, CRN, Lisa Cook, CRN, Sophia Grasmeder, CRN, Philip Scheinberg, MD, Neal S. Young, MD, Sumithira Vasu, MD, Theresa Donohue, MHS, PA-C, Richard Childs, MD

Blood (2010) 116 (21): 517.

https://doi.org/10.1182/blood.V116.21.517.517

Published: 2010

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial

Trials in progress: Design of a registrational Phase 2 trial (ALLOHA) using an external control arm for TSC-101 for prevention of relapse post allogeneic HCT in patients with ALL, AML, or MDS

Primary results from Equator, a Phase 3 double-blind, randomized placebo-controlled study evaluating itolizumab in combination with corticosteroids as initial treatment of acute graft-versus-host disease.

Orca-T improves chronic graph-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, Phase 3 trial

Observational comparison of orca-T to registry-based post-transplant cyclophosphamide patients using matched unrelated donors

High-dose cryopreserved bone marrow from deceased donors may reduce relapse in HLA-mismatched allogeneic transplantation: Day 180 post-transplant HOPE update

Healthcare Resource Utilization and Costs Associated with Managing CRS and ICANS in Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Receiving Obecabtagene autoleucel (obe-cel)

Comparison of 15- Vs. 30-Day Remote Patient Monitoring for Outpatient Chimeric Antigen Receptor T-Cell Therapy (CAR-T) across a Large Health System

Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients

Standardization of Outpatient Care after CAR-T Therapy across a Large Cell Therapy Network- through Technology and Decentralized Virtual Nurses: Preliminary Results

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)

Indoximod Combined with Standard Induction Chemotherapy Is Well Tolerated and Induces a High Rate of Complete Remission with MRD-Negativity in Patients with Newly Diagnosed AML: Results from a Phase 1 Trial

Intrabone Delivery of CD34+ Cells Using an Optimized Delivery System Does Not Enhance Engraftment in a Rhesus Macaque Model of Hematopoietic Stem Cell Transplantation

Molecular Characterization By Cancer Immune Profiling in Acute Promyelocytic Leukemia (APL) May Identify Patients at Risk of Early Death

Intermediate-Dose Cyclophosphamide Versus Plerixafor and Granulocyte Colony Stimulating Factor (G-CSF) for Peripheral Blood Progenitor Cell (PBPC) Mobilization in Patients with Multiple Myeloma (MM) Treated with Novel Induction Chemotherapies – A Multicenter Analysis

Co-Infusion of Allogeneic Cord Blood with Haploidentical CD34+ Cells Improved Transplant Outcome for Patients with Severe Aplastic Anemia Undergoing Cord Blood Transplantation

A Phase I Trial of Adoptively Transferred Ex-Vivo Expanded Autologous Natural Killer (NK) Cells Following Treatment with Bortezomib to Sensitize Tumors to NK Cell Cytotoxicity

Adoptive Transfer of Escalating Doses of Ex Vivo Expanded Autologous Natural Killer (NK) Cells In Patients with Advanced Malignancies Following Bortezomib Treatment to Sensitize to NK-TRAIL Cytotoxicity

Long-Term Follow-up of Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Severe Paroxysmal Nocturnal Hemoglobinuria

Absence of Graft Failure and Excellent Long Term Survival Following Fludarabine-Based Reduced Intensity Hematopoietic Stem Cell Transplantation In Heavily Transfused Patients with ATG-Refractory Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only